Glenmark Associates, Inc.

What Glenmark Associates, Inc. does

Glenmark Associates, Inc. operates as Glenmark Pharmaceuticals Inc., USA, a wholly-owned US subsidiary of Glenmark Pharmaceuticals Ltd. (a publicly traded Indian pharmaceutical company headquartered in Mumbai). Founded in 2003 and headquartered in Elmwood Park, New Jersey, the company develops, manufactures, and distributes generic prescription pharmaceuticals, over-the-counter (OTC) products, and injectable medications for the US market. Its core technology focuses on complex generic formulations including oral solids, sterile injectables, and nebulizer products manufactured at a first-of-its-kind 100,000-square-foot Monroe, North Carolina facility, with anticipated capacity of 20-25 million vials and prefilled syringes, 25-30 million ampules, and 300-350 million tablets and capsules annually.

The company maintains an FDA-approved portfolio of over 100 generic products in the US with at least 60 more pending approval, spanning therapeutic areas including oncology, respiratory diseases, schizophrenia, bipolar disorder, ADHD, allergic rhinitis, and anticoagulation. Recent significant launches include Sugammadex Injection (generic of BRIDION, entering a ~$1.6 billion market), Olanzapine for Injection (generic of Zyprexa), Phytonadione Injectable Emulsion (generic of Vitamin K1), and Ryaltris nasal spray for seasonal allergic rhinitis. The business operates through three core product segments: Generics (Rx), Over-the-Counter (OTC), and Injectable/Institutional Products.

Glenmark's commercial model combines direct institutional sales to US hospitals with distribution through authorized wholesale distributors (with Inmar RX Solutions handling returns processing). The company transitioned in April 2026 to direct commercialization of its Ryaltris respiratory product, signaling expanded proprietary commercial capabilities. Additional operational footprint includes a 159,865-square-foot VAWD-accredited distribution center in Allentown, Pennsylvania (built in 2023), and a Canada presence. The entity operates under New Jersey jurisdiction and is a wholly-owned subsidiary of the Indian-listed parent company, which is included in the Dow Jones Sustainability Index.

Name

Glenmark Associates, Inc.

Legal name

Glenmark Pharmaceuticals Inc., USA

Website

https://glenmarkpharma-us.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Glenmark Associates, Inc. (Glenmark Pharmaceuticals Inc., USA) is a US subsidiary of India's Glenmark Pharmaceuticals Ltd. that develops, manufactures, and distributes generic prescription drugs, OTC products, and injectable medications, serving US hospitals, institutional healthcare providers, and patients through wholesale distributors and direct institutional sales.

Ownership category

akta.pro rank

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Generic pharmaceutical products
• Sterile injectable manufacturing
• Hospital institutional medications
• Over-the-counter pharmaceuticals
• Prescription drug distribution

Headquarters

HQ city

Elmwood Park

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Prescription Drugs (Rx): Development and commercialization of generic prescription pharmaceutical products including oral solids and injectable medications for US hospitals and institutional use.
2. Over-the-Counter (OTC) Products: Production and sale of OTC generic pharmaceutical products directly to consumers and through retail channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Glenmark Pharmaceuticals Inc., USA develops, manufactures, and commercializes generic prescription (Rx) drugs, over-the-counter (OTC) products, and injectable medications for U.S. hospitals and institutional healthcare channels. The portfolio includes more than 100 FDA-approved generic products with at least 60 more pending approval, plus a growing institutional injectables franchise (Sugammadex, Olanzapine, Phytonadione) and the Ryaltris nasal spray for allergic rhinitis.

Product overview

Glenmark Pharmaceuticals Inc., USA is a pharmaceutical company offering a diversified portfolio of products organized into three core segments: Generics (Rx), Over-the-Counter (OTC), and Injectable/Institutional Products. The Generics portfolio includes more than 100 approved products with at least 60 more pending approval. OTC provides low-cost accessible products. The Injectable/Institutional segment has been expanding rapidly with recent launches including Sugammadex Injection (neuromuscular blockade reversal, $1.6B market), Olanzapine for Injection (antipsychotic, $25.4M market), and Phytonadione Injectable Emulsion (anticoagulant, $19.7M market). Ryaltris nasal spray represents the company's respiratory franchise. The company also operates distribution operations from Allentown, PA and manufacturing in Monroe, NC.

Differentiator

Problem solved

Functional benefit

Products and services

• Generics (Rx) A portfolio of FDA-approved generic prescription drugs including oral solids and injectables aimed at reducing healthcare costs and delivering quality medicines; more than 100 products approved in the U.S. with at least 60 more pending approval.
• Over-the-Counter (OTC) Products

Quantifiable outcome

• 100+ generic products approved in the US market
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Inmar RX Solutions Inc.coreChannel Partner/ Reseller/ DistributorThird-party returns processing partner for handling product returns through their secure portal at hrm.reskureturns.com. Manages debit memo processing, return authorizations, and secure return shipping to Grand Prairie, Texas facility.
• Boys & Girls Club of Hackensack and LodiminorOthersCommunity partner receiving support through Glenmark's annual 'Joy of Giving' volunteering initiative and corporate giving program.
• Greater Bergen Community ActionminorOthersCommunity partner receiving support through Glenmark's annual 'Joy of Giving' volunteering initiative and corporate giving program.
• National Breast Cancer FoundationminorOthersNonprofit partner receiving corporate donations and support through Glenmark's corporate social responsibility and 'Joy of Giving' program.
• The Center for Food ActionminorOthersCommunity partner receiving support through Glenmark's annual 'Joy of Giving' volunteering initiative and corporate giving program.
• Susan G. Komen for the CureminorOthersNonprofit breast cancer research organization receiving corporate donations and support through Glenmark's corporate social responsibility program.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fresenius Kabi: Major global injectable and infusion therapy specialist with deep US hospital footprint; direct competitor to Glenmark's Sugammadex, Olanzapine, and Phytonadione injectable launches.
• Sagent Pharmaceuticals: US-focused specialty injectables company (now part of Strides group); closely comparable to Glenmark's hospital injectables portfolio and channel strategy.
• Zydus Pharmaceuticals (Zydus Cadila): India-based generic manufacturer with a substantial US subsidiary; competes with Glenmark across oral solids, injectables, and specialty generics, particularly in the institutional channel.
• Dr. Reddy's Laboratories: India-headquartered global generic pharmaceutical company with a major US subsidiary; overlaps directly with Glenmark in oral solids, injectables, and OTC generics sold into US hospital and retail channels.
• Hikma Pharmaceuticals: Specialty generic and injectable manufacturer with a strong US institutional/hospital franchise; competes head-to-head with Glenmark in sterile injectables (including anesthesia reversal) and complex generics.
• Amneal Pharmaceuticals: US-based generics and specialty pharma manufacturer with a large injectables franchise; competes directly with Glenmark in hospital injectables and affordable generic injectables.
• Aurobindo Pharma USA: US subsidiary of Indian generic major Aurobindo Pharma; competes with Glenmark across US generics, injectables, and OTC with a similarly broad 100+ SKU portfolio.
• Apotex: Canadian-based global generic manufacturer with US operations; competes with Glenmark across oral solids, injectables, and OTC generics, particularly in hospital channels.

Broad incumbents

• Sandoz (Novartis): Global generic leader (now Novartis subsidiary) with major US presence in oral solids, biosimilars, and injectables; competes with Glenmark across nearly all generic categories and at greater scale.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with an extensive US portfolio across oral solids, injectables, and OTC; overlaps broadly with Glenmark's generic portfolio but at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/glenmark-north-america

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glenmark Associates, Inc.